{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Single+Dose+Placebo&page=94",
    "query": {
      "intervention": "Single Dose Placebo",
      "page": 94
    },
    "page_size": 10
  },
  "pagination": {
    "page": 94,
    "page_size": 10,
    "total_count": 4634,
    "total_pages": 464,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Single+Dose+Placebo&page=95&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Single+Dose+Placebo&page=93&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T16:21:01.572Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02205814",
      "title": "Fasitibant Intra-articular Injection in Patients With Symptomatic Osteoarthritis of the Knee",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Knee Osteoarthritis"
      ],
      "interventions": [
        {
          "name": "Fasitibant- low dose",
          "type": "DRUG"
        },
        {
          "name": "Fasitibant- intermediate dose",
          "type": "DRUG"
        },
        {
          "name": "Fasitibant- high dose",
          "type": "DRUG"
        },
        {
          "name": "Placebo comparator",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Menarini Group",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 436,
      "start_date": "2014-04",
      "completion_date": "2015-01",
      "has_results": true,
      "last_update_posted_date": "2015-11-03",
      "last_synced_at": "2026-11-19T16:21:01.572Z",
      "location_count": 9,
      "location_summary": "Tucson, Arizona • Englewood, Colorado • DeLand, Florida + 5 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Englewood",
          "state": "Colorado"
        },
        {
          "city": "DeLand",
          "state": "Florida"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02205814"
    },
    {
      "nct_id": "NCT02238626",
      "title": "Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Amyotrophic Lateral Sclerosis"
      ],
      "interventions": [
        {
          "name": "Placebo (for MN-166)",
          "type": "DRUG"
        },
        {
          "name": "MN-166",
          "type": "DRUG"
        },
        {
          "name": "riluzole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MediciNova",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 70,
      "start_date": "2014-09",
      "completion_date": "2017-12",
      "has_results": true,
      "last_update_posted_date": "2021-11-05",
      "last_synced_at": "2026-11-19T16:21:01.572Z",
      "location_count": 1,
      "location_summary": "Charlotte, North Carolina",
      "locations": [
        {
          "city": "Charlotte",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02238626"
    },
    {
      "nct_id": "NCT00749411",
      "title": "Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "GSK233705/GW642444",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 61,
      "start_date": "2008-11-13",
      "completion_date": "2009-02-12",
      "has_results": true,
      "last_update_posted_date": "2020-09-01",
      "last_synced_at": "2026-11-19T16:21:01.572Z",
      "location_count": 12,
      "location_summary": "Mobile, Alabama • Wheat Ridge, Colorado • Biddeford, Maine + 9 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Wheat Ridge",
          "state": "Colorado"
        },
        {
          "city": "Biddeford",
          "state": "Maine"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Summit",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00749411"
    },
    {
      "nct_id": "NCT05718921",
      "title": "A Safety, Tolerability and Pharmacokinetics Study of Topical Ointment YR001 in Adult Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Atopic Dermatitis",
        "Psoriasis"
      ],
      "interventions": [
        {
          "name": "YR001 Dose A on low body surface area",
          "type": "DRUG"
        },
        {
          "name": "YR001 Dose A on middle body surface area",
          "type": "DRUG"
        },
        {
          "name": "YR001 Dose A on high body surface area",
          "type": "DRUG"
        },
        {
          "name": "YR001 Dose B on low body surface area",
          "type": "DRUG"
        },
        {
          "name": "YR001 Dose B on middle body surface area",
          "type": "DRUG"
        },
        {
          "name": "YR001 Dose B on high body surface area",
          "type": "DRUG"
        },
        {
          "name": "Placebo on low body surface area",
          "type": "DRUG"
        },
        {
          "name": "Placebo on middle body surface area",
          "type": "DRUG"
        },
        {
          "name": "Placebo on high body surface area",
          "type": "DRUG"
        },
        {
          "name": "YR001 Dose A on high body surface area twice daily",
          "type": "DRUG"
        },
        {
          "name": "YR001 Dose B on high body surface area twice daily",
          "type": "DRUG"
        },
        {
          "name": "Placebo on high body surface area twice daily",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hangzhou Yirui Pharmaceutical Technology Co., Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 54,
      "start_date": "2023-04-08",
      "completion_date": "2023-12-14",
      "has_results": false,
      "last_update_posted_date": "2024-01-24",
      "last_synced_at": "2026-11-19T16:21:01.572Z",
      "location_count": 1,
      "location_summary": "Encinitas, California",
      "locations": [
        {
          "city": "Encinitas",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05718921"
    },
    {
      "nct_id": "NCT01127321",
      "title": "A Safety and Tolerability Study of MEDI-570 in Systemic Lupus Erythematosus",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lupus Erythematosus, Systemic"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "MEDI-570 0.03 MG",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MEDI-570 0.1 MG",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MEDI-570 0.3 MG",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MEDI-570 1 MG",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "MedImmune LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 44,
      "start_date": "2010-05",
      "completion_date": "2012-07",
      "has_results": true,
      "last_update_posted_date": "2014-08-26",
      "last_synced_at": "2026-11-19T16:21:01.572Z",
      "location_count": 9,
      "location_summary": "Long Beach, California • San Leandro, California • Fort Lauderdale, Florida + 6 more",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "San Leandro",
          "state": "California"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "Ocala",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01127321"
    },
    {
      "nct_id": "NCT04680026",
      "title": "A Study of IV HBI-3000 for the Conversion Recent Onset Atrial Fibrillation (AF)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Atrial Fibrillation"
      ],
      "interventions": [
        {
          "name": "HBI-3000",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "HUYABIO International, LLC.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 150,
      "start_date": "2021-06-01",
      "completion_date": "2025-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-12-02",
      "last_synced_at": "2026-11-19T16:21:01.572Z",
      "location_count": 4,
      "location_summary": "Naples, Florida • Springfield, Illinois • Tupelo, Mississippi + 1 more",
      "locations": [
        {
          "city": "Naples",
          "state": "Florida"
        },
        {
          "city": "Springfield",
          "state": "Illinois"
        },
        {
          "city": "Tupelo",
          "state": "Mississippi"
        },
        {
          "city": "Tyler",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04680026"
    },
    {
      "nct_id": "NCT01052506",
      "title": "BIIB033 Single Ascending Dose Study in Healthy Volunteer Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "BIIB033",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "25 Years to 55 Years"
      },
      "enrollment_count": 72,
      "start_date": "2010-01",
      "completion_date": "2011-10",
      "has_results": false,
      "last_update_posted_date": "2017-01-09",
      "last_synced_at": "2026-11-19T16:21:01.572Z",
      "location_count": 1,
      "location_summary": "Glendale, California",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01052506"
    },
    {
      "nct_id": "NCT01632579",
      "title": "A Single Dose Study of LY3023703 in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "LY3023703",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Celecoxib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 30,
      "start_date": "2012-06",
      "completion_date": "2012-09",
      "has_results": true,
      "last_update_posted_date": "2018-08-06",
      "last_synced_at": "2026-11-19T16:21:01.572Z",
      "location_count": 1,
      "location_summary": "Evansville, Indiana",
      "locations": [
        {
          "city": "Evansville",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01632579"
    },
    {
      "nct_id": "NCT02239562",
      "title": "sPIF CLINICAL STUDY PROTOCOL IN AUTOIMMUNE HEPATITIS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Autoimmune Hepatitis"
      ],
      "interventions": [
        {
          "name": "sPIF",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Christopher O'Brien, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 70 Years · Female only"
      },
      "enrollment_count": 36,
      "start_date": "2014-11-14",
      "completion_date": "2016-12-29",
      "has_results": true,
      "last_update_posted_date": "2019-11-20",
      "last_synced_at": "2026-11-19T16:21:01.572Z",
      "location_count": 2,
      "location_summary": "Miami, Florida • Cherry Hill, New Jersey",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Cherry Hill",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02239562"
    },
    {
      "nct_id": "NCT02069366",
      "title": "Cannabinoid Control of Fear Extinction Neural Circuits in Post-traumatic Stress Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Post-Traumatic Stress Disorder"
      ],
      "interventions": [
        {
          "name": "Dronabinol",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wayne State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "21 Years to 45 Years"
      },
      "enrollment_count": 86,
      "start_date": "2014-11",
      "completion_date": "2019-12",
      "has_results": true,
      "last_update_posted_date": "2025-10-02",
      "last_synced_at": "2026-11-19T16:21:01.572Z",
      "location_count": 1,
      "location_summary": "Detroit, Michigan",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02069366"
    }
  ]
}